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Background: A O30% N-terminal proeB-type natriuretic peptide (NT-proBNP) reduction at discharge
in acute decompensated heart failure (ADHF) predicts a favorable prognosis. To study the feasibility of
guiding ADHF treatment by measuring NT-proBNP well before discharge, we assessed at which moment
during hospitalization patients attain a NT-proBNP reduction ofO30% (target) and whether this target is
still attained at discharge.
Methods: Twenty-five consecutive ADHF patients with NT-proBNP O1,700 ng/L were included (orig-
inal cohort). NT-proBNP was measured daily until the target was attained, at clinical stability, and at
discharge and was analyzed as percentages of patients on target. For comparison purposes, the same anal-
ysis was performed in individual patient data from 2 other ADHF cohorts (42 and 111 patients, respec-
tively), in which NT-proBNP was measured from admission to day 3 and at discharge.
Results: In the original cohort of 25 patients (median age 70 years, 40% male), the cumulative percentage
of patients attaining the target increased gradually during admission to 22 patients (88%) in a median of
3 days (interquartile range 2e5). In the comparison cohorts, a similar course was observed in patients
attaining the target before discharge. Compared with levels measured at days 2 and 3, rebound
NT-proBNP increases to levels off-target at discharge were seen in up to 33% of patients in the original
and comparison cohorts.
Conclusion: A target O30% NT-proBNP reduction is gradually attained before discharge, and rebound
NT-proBNP increases to levels off-target occur in up to 33% of ADHF patients who initially attained
target early during admission. (J Cardiac Fail 2015;21:930e934)
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Hospital admissions for acute decompensated heart fail-
ure (ADHF) are frequent and accompanied by high percent-
ages of mortality and readmissions.1 The best predictors of
prognosis in ADHF patients appear to be plasma B-type
natriuretic peptide (BNP) and the inactive N-terminal frag-
ment of its precursor pro-BNP, NT-proBNP,2e6 indicators
of ventricular wall stretch.7 Several studies have demon-
strated that a relative NT-proBNP reduction of #30% at
discharge for ADHF is a significant predictor of readmis-
sions and mortality.2,3,6,8 A role for NT-proBNPeguided
ADHF treatment targeting a reduction of O30% is there-
fore suggested.9 Whether an NT-proBNP target can be set
at a time point well before discharge (at, eg, day 2 or 3)
is unknown. The advantage of an early measurement would
be to be able to adjust therapy within the usual time of
admission. In contrast, an NT-proBNP measurement too
early during admission may predate clinical circumstances
that increase NT-proBNP levels again (such as worsening
of heart failure [HF]). More NT-proBNP measurements
are then warranted to ascertain that patients are discharged
with a reduction of O30%.
To study the feasibility of performing an NT-proBNP
measurement well before discharge with the future possibil-
ity to guide ADHF treatment targeting a O30%
NT-proBNP reduction, we assessed the moment at which
hospitalized patients attain this reduction and determined
the percentage of patients who experienced rebound
NT-proBNP increases to levels off-target at discharge.
Methods
Original Cohort
Daily NT-proBNP measurements were performed in 25 consec-
utive ADHF patients in a prospective substudy of the PRIMA II
(hereafter named original cohort) enrolled from May 2012 to
June 2013 in the Academic Medical Center in Amsterdam, The
Netherlands. Rationale and design of the study have been previ-
ously reported.9 This substudy was approved by the Medical
Ethics Committee of the University of Amsterdam and Academic
Medical Center, The Netherlands, and written informed consents
were obtained from all patients.
From admission (day 0), daily NT-proBNP measurements were
performed until a O30% reduction (target) was attained, at
randomization, and at discharge. Patients were randomized on
the day of clinical stability, a discharge criterion requiring the
presence of 3 of 4 clinical variables.9 No attempts were made to
adjust therapy using these measurements before randomization.
In patients subjected to conventional therapy, NT-proBNP mea-
surements at randomization and discharge were blinded. In
patients subjected to NT-proBNPeguided therapy, additional
treatment options were reconsidered only after randomization
and if applicable adjusted to attain target.
Analysis
In the original cohort, we evaluateddfor each day of
admissiondthe cumulative percentages of patients on target. Per-
centage of patients on target was also determined at the day of
discharge. Percentages of patients that were on target at day 2
and 3 of admission but demonstrated a rebound NT-proBNPincrease to levels off-target at discharge (hereafter named rebound
NT-proBNP increase) were determined. Categoric variables are re-
ported as frequencies and percentages; continuous variables are
reported as mean 6 SD or as median and interquartile range
(IQR).
Comparison Cohorts
We analyzed individual data from 2 ADHF prospective regis-
tries for comparison of the results of the original cohort for the
time-dependent course of patients attaining target during admis-
sion and rebound NT-proBNP increases between days 2 and 3
and discharge.10,11 In the Rome cohort (n 5 42), NT-proBNP
was measured at admission, after 12, 24, 48, and 72 hours, and
at discharge.10 In the Brescia cohort (n 5 121), NT-proBNP was
measured at admission, after 6, 12, 24, and 48 hours, and at
discharge.11 We excluded 10 patients from the Brescia cohort
for having a noncardiovascular cause of admission or for presence
of multiple missing NT-proBNP values. Physicians in these co-
horts were blinded for the NT-proBNP results.
Baseline characteristics and cumulative percentages of patients
attaining target between cohorts were compared with the use of
either Student t or Mann-Whitney U test where appropriate for
continuous and chi-square test for categoric variables.
Results
Original Cohort
Baseline characteristics of the original cohort are listed
in Table 1. None of the patients died during admission.
The percentage of patients that attained the target during
admission is depicted cumulatively in Figure 1. The target
was gradually attained in 22 patients (88%) in a median of
3 days (IQR 2e5). Of the patients on target at days 2 and 3,
0% (0/9) and 8% (1/13), respectively, demonstrated a
rebound NT-proBNP increase. In total, 4 of the patients
that attained the target throughout the hospitalization
demonstrated a rebound NT-proBNP increase. Clinical cir-
cumstances that could explain this NT-proBNP increase
were development of a gastroenteritis (n 5 1), atrial fibril-
lation (n 5 1), cardiogenic shock after complete AV block
(n 5 1), and HF medication down-titration after experi-
encing lightheadedness (n 5 1). Three patients did not
attain the target during admission and discharge.
Thus, of 22 patients initially on target, 18 patients (72%)
were discharged on target.
Comparison Cohorts
Baseline characteristics of the comparison cohorts are
also listed in Table 1. The cohorts were heterogeneous,
particularly regarding age, left ventricular ejection fraction,
admission blood urea nitrogen and NT-proBNP levels, and
intravenous furosemide starting doses.
Significant differences in percentages of patients attain-
ing the target between the Rome and original cohort were
observed at discharge (Fig. 2). The Brescia cohort showed
significant differences in cumulative percentages of patients
attaining the target at days 1 and 2 and discharge (Fig. 2).
In patients that attained the target at day 2, a rebound
Table 1. Baseline Characteristics of Original and Comparison Cohorts
Variable
Original Cohort Comparison Cohorts
Amsterdam (n 5 25) Brescia (n 5 111) Rome (n 5 42)
Age, y, median (IQR) 70 (59e78) 68 (59e74) 78 (72e82)*
Age $75 y, n (%) 11 (44) 26 (23) 29 (69)
Male, n (%) 15 (60) 100 (90)*** 28 (67)
History of DM, n (%) 9 (36) 39 (35) 12 (29)
History of hypertension, n (%) 14 (56) 47 (42) 29 (69)
History of CHF, n (%) 22 (88) NA 31 (74)
Ischemic etiology, n (%) 10 (40) 57 (52) 21 (50)
LVEF, n (%)
Preserved ($45%) 1 (4) 14 (13) 15 (36)
Mild-moderate (25%e44%) 15 (60) 49 (46) 25 (60)***
Severe (!25%) 9 (36) 43 (41) 2 (5)
JVP distended at admission, n (%) 12 (52) 46 (41) NA
Pulmonary rales at admission, n (%) 17 (68) 97 (87)* 31 (74)
Peripheral edema at admission, n (%) 18 (72) 59 (53) 34 (81)
SBP at admission, mm Hg, mean 6 SD 127 6 30 120 6 30 136 6 18
DBP at admission, mm Hg, mean 6 SD 75 6 20 75 6 15 71 6 11
Heart rate at admission, beats/min, mean 6 SD 92 6 28 87 6 21 84 6 23
Atrial fibrillation at admission, n (%) 10 (40) 42 (38) 20 (48)
NYHA functional class at admission, n (%)
I 0 (0) 0 (0) 0 (0)
II 3 (13) 7 (7) 6 (14)
III 13 (54) 53 (49) 19 (45)
IV 8 (33) 48 (44) 17 (41)
Laboratory findings, mean 6 SD
Hemoglobin at admission, g/L 7.8 6 1.5 8.1 6 1.8 7.4 6 1.3
Serum urea nitrogen at admission, mmol/L 15.6 6 9.1 31.4 6 20*** 13 6 7.1
Serum sodium at admission, mmol/L 136 6 5 137 6 4 138 6 6
Serum potassium at admission, mmol/L 4.2 6 0.6 4.3 6 0.6 4.2 6 0.7
eGFR at admission, mL min1 1.73 m2y 46 6 25 57 6 29 49 6 27
NT-proBNP at admission, pg/mL, median (IQR) 7,491 (5,470e18,032) 4,740 (1,735e9,528)** 5,956 (2,285e13,723)
Duration admission, days, mean 6 SD 19 6 18 15 6 11 NA
Medication at admission, n (%)
Diuretics 23 (92) 95 (86) 34 (81)
Aldosterone antagonist 9 (36) 55 (50) 10 (24)
ACE-inhibitor 10 (40) 63 (57) 19 (45)
Angiotensin II receptor blocker 5 (20) 17 (16) 8 (19)
Beta blocker 20 (80) 71 (65) 16 (38)**
Furosemide starting dose at admission, mg, median (IQR) 160 (125e250) 250 (200e500)* 50 (20e174)***
IQR, interquartile range; SD, standard deviation; DM, diabetes mellitus; CHF, congestive heart failure; LVEF, left ventricle ejection fraction; JVP, jugular
venous pressure; SBP, systolic blood pressure; DPB, diastolic blood pressure; NYHA, New York Heart Association; eGFR, estimated glomerular filtration
rate.
*P ! .05; **P ! .01; ***P ! .001 (comparison between comparison cohorts and original cohort).
yCalculated as 186.3  (creatinine mg/dL)1.154  (age)0.203  (0.742 if female)  (1.210 if black).
Fig. 1. Cumulative percentage of patients attaining a reduction
ofO30% in N-terminal proeB-type natriuretic peptide levels dur-
ing admission in the original (Amsterdam) and 2 comparison
cohorts.
932 Journal of Cardiac Failure Vol. 21 No. 11 November 2015NT-proBNP increase was seen in 9% (1/11) and 33%
(22/67) of patients in the Rome and Brescia cohorts, respec-
tively. From day 3, 20% of patients (3/15) from the Rome
cohort who attained the target demonstrated a rebound
NT-proBNP increase.
Discussion
Our results suggest that 1) ADHF patients attain a target
NT-proBNP reduction of O30% gradually during admis-
sion and 2) rebound NT-proBNP increases to levels off-
target at discharge occur in patients who attained target
early during admission (ie, day 2 or 3).
Gradual Increase in Patients Attaining Target
We observed a gradual increase in cumulative percentage
of patients that attain target during admission in all 3 co-
horts. The observed percentages of patients on target at
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Fig. 2. Cumulative percentage of patients attaining a reduction
of O30% in N-terminal proeB-type natriuretic peptide
(NT-proBNP) levels on days 1, 2, and 3 of admission and at
discharge in different acute decompensated heart failure cohorts.
*Statistically significant difference between the results from the
original (Amsterdam) and comparison cohorts.
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There are some interesting differences between cohorts:
especially at day 1 and 2, significantly more patients
attained the target in the Brescia cohort compared with
the original cohort. One of the possible explanations is a
higher dose of diuretics used in Brescia. The Diuretics
Optimization Strategies Evaluation in ADHF (DOSE) trial
demonstrated a trend for a greater absolute reduction in
NT-proBNP with higher doses of furosemide during
ADHF admissions compared with administration of low-
dose diuretics.12
Rebound NT-proBNP Increases
In both the original and the comparison cohorts, up to
33% of patients experienced rebound NT-proBNP increases
at discharge when they initially had attained the target at
day 2 and 3 of admission. In the original cohort, there
were 3 additional patients who demonstrated rebound
NT-proBNP increases after day 3, suggesting that rebound
increases may occur throughout the entire course of
admission.
Various causes for reelevation of natriuretic peptide levels
exist, such as cardiac arrhythmias, coronary ischemia, etc.13
Searching for an explanation for this reboundNT-proBNP in-
crease, we found that for each of these patients in the original
cohort, it could potentially be attributed to cardiovascular
deteriorating circumstances. Whether a rebound increase in
NT-proBNP is always a surrogate marker of clinical deterio-
rating circumstances, or alternatively a recovery from under-
filling, warrants further investigation.
Besides changes related to congestion, changes in
NT-proBNP levels due to biologic variation should be
considered. Studies on short-term biologic variation ofNT-proBNP in chronic HF patients are limited and demon-
strate variations up to 100% change, but these subclinical
changes in NT-proBNP might have been caused by (sub-
clinical) signs of worsening HF.14 A O30% NT-proBNP
reduction is near biologic variation levels, but has been
found to be clinically meaningful in several end-point
studies.2,3,5,6,8
Study Limitations
This study had a small sample size, and results should
therefore be interpreted with caution. Some of this limitation
was overcome by describing additional (unpublished) find-
ings from 2 other ADHF cohorts. Another limitation is the
heterogeneity of patients and treatments in the cohorts, as
exemplified in the use of different furosemide starting doses,
and any comparison between cohorts should be carefully
interpreted. Additionally, NT-proBNP results in the original
cohort were known to the treating physician (with the
exception of levels at randomization and discharge for the
conventional group), whereas they were not known in the
comparison cohorts. However, after attaining target at day 2
or 3, NT-proBNP measurements were not performed until
days of randomization and discharge. Of the 9 patients who
were randomized to NT-proBNPeguided therapy, 2 patients
were off-target at randomization and at discharge despite
guidance, whereas the remaining 7 patients were on target
at both moments. Therefore, guidance is not likely to have
influenced the percentage of patients experiencing rebound
NT-proBNP increases.
Conclusion
When the intention is to guide ADHF treatment with a
target of O30% NT-proBNP reduction, one should be
aware that the percentage of patients attaining target during
admission is influenced both by a gradual increase in pa-
tients on target toward the end of admission and by occur-
rence of rebound NT-proBNP increases.
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